PatientsVille.com Logo


Daonil Medical Research Studies

Up-to-date List of Daonil Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Daonil Medical Research Studies

Rank Status Study
1 Recruiting Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hypoglycemic Agents;   Diabetic Blood Glucose Monitoring;   Exercise
Interventions: Drug: MET + Vildagliptin Group;   Drug: MET + Glibenclamide Group
Outcome Measures: Change in Glycemic variability;   Change in Hemodynamic response to exercise: Cardiac output (Q), Stroke Volume (SV) and blood pressure (BP)
2 Recruiting Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension
Conditions: Type 2 Diabetes Mellitus;   Hypertension;   Endothelial Dysfunction
Interventions: Drug: Glibenclamide;   Drug: Vildagliptin
Outcome Measures: Change from baseline in the reactive hyperemia index (RHI) after 12 weeks of vildagliptin x glibenclamide treatment;   Change from baseline in the central blood pressure after 12 weeks of vildagliptin x glibenclamide treatment
3 Recruiting Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
Condition: Traumatic Brain Injury
Interventions: Drug: Glyburide;   Drug: Placebo
Outcome Measures: Change in Edema from Baseline;   Change in Hemorrhage from Baseline;   Safety i.e. the incidence of mortality, adverse events, and serious adverse events
4 Recruiting Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
Conditions: Ischemic Stroke;   Malignant Edema
Intervention: Drug: RP-1127 (Glyburide for Injection)
Outcome Measures: The proportion of patients with a modified Rankin Scale (mRS) at Day 90 ≤ 4 without decompressive craniectomy;   Safety of RP-1127 in subjects with a severe anterior circulation ischemic stroke who are likely to develop malignant edema.;   Proportion of subjects that develop malignant edema;   Proportion of subjects undergoing DC, and DC-associated AEs and SAEs;   Proportion of subjects that experience early neurological deterioration;   Proportion of subjects that develop parenchymal hematomas;   Ipsilateral hemispheric swelling measured by MRI;   Proportion of subjects with 90 day mRS 0-3 and 0-4;   Activities of Daily Living (as measured by the Barthel Index) at 90 days;   All-cause mortality at 90 days
5 Recruiting Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)
Condition: Gestational Diabetes Mellitus
Interventions: Drug: Glyburide;   Drug: Metformin;   Drug: Glyburide-Metformin combination
Outcome Measures: Study drug dosage in pregnancy;   Determine GLY and MET PK parameters
6 Recruiting Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide
Condition: Gestational Diabetes
Interventions: Drug: Glyburide;   Device: Continuous glucose monitor
Outcome Measure: Glucose levels throughout the day
7 Recruiting Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes
Conditions: Diabetes;   Gestational
Interventions: Other: Insulin;   Drug: Glyburide
Outcome Measures: Composite criterion of neonatal complications associated with gestational diabetes: macrosomia or birth weight ≥ 90th percentile for gestational age, neonatal hypoglycemia and neonatal hyperbilirubinemia;   Rates of caesarean section, preterm delivery rate, neonatal mortality rate, number of neonatal and maternal trauma related to delivery, number of respiratory distress, number of prenatal visits, number of days of hospitalization
8 Not yet recruiting A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS
Conditions: Pregnancy;   Gestational Diabetes
Interventions: Drug: Glibenclamide;   Drug: Insulin
Outcome Measures: Number of women willing to be randomised;   Glycaemic control;   Patient satisfaction;   Clinical outcomes;   Clinical outcome;   Clinical Outcome
9 Unknown  Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo
Condition: Mild Gestational Diabetes
Interventions: Drug: Glyburide;   Drug: Placebo
Outcome Measures: Fetal weight reduction of 200gm with Glyburide treatment;   Large for gestational age infants;   Macrosomia;   Neonatal Intensive Care Unit admissions;   Rate of cesarean delivery;   Risk of preeclampsia;   Time to achieve glycemic control;   Need for insulin treatment
10 Unknown  Treatment of Mild Gestational Diabetes With Glyburide Compared to Placebo
Conditions: Gestational Diabetes;   Pregnancy Complications
Interventions: Drug: Glyburide;   Drug: Placebo;   Behavioral: ADA diet + nutritional counseling
Outcome Measures: Fetal weight reduction of 200 gm;   Large for gestational age infants;   Macrosomia;   Neonatal Intensive Care Unit admissions;   Risk of preeclampsia;   Rate of cesarean delivery;   Time to achieve glycemic control;   Need for insulin treatment
11 Not yet recruiting Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Vildagliptin;   Drug: Glibenclamide
Outcome Measures: Absolute and relative change in the EPC number;   Absolute and relative change in HbA1C compared to baseline
12 Not yet recruiting Cardioprotective Effects of GLP-1 and Their Mechanisms
Condition: Angina Pectoris
Interventions: Drug: GLP-1 (7-36) amide;   Drug: Glibenclamide
Outcome Measures: Change in Isovlumetric Relaxation Constant - Tau (ms);   Left Ventricular Ejection Fraction (%);   Maximal rate of change with time of left ventricular pressure - dP/dt max (mmHg/s);   Minimum rate of change with time of left ventricular pressure - dP/dt min (mmHg/s)
13 Recruiting Oral Antidiabetic Agents in Pregnancy
Condition: Gestational Diabetes
Interventions: Drug: Metformin;   Drug: Glyburide
Outcome Measures: fetal growth;   insulin requirements to achieve glucose targets
14 Unknown  The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation
Conditions: Diabetes Mellitus;   Arterial Stiffness
Interventions: Drug: sitagliptin;   Drug: glibenclamide
Outcome Measures: arterial stiffness, defined as change in augmentation index measured by means of a non-invasive technique using the commercially available SphygmoCor System, and the results of the 24 hour blood pressure monitoring;   The secondary end results would be oxidative stress parameters, as evaluated by oxidized LDL and Isoprostanes, and markers of inflammatory status, including measurements of pro-inflammatory interleukins and performance of highly sensitive CRP test.
15 Unknown  Comparison of Glucovance to Insulin for Diabetes During Pregnancy
Conditions: Gestational Diabetes;   Type 2 Diabetes;   Pregnancy
Intervention: Drug: Insulin versus glucovance (glyburide/metformin)
Outcome Measures: Maternal hemoglobin A1C at delivery;   Maternal fructosamine at delivery;   Maternal glucose at delivery;   Mode of delivery;   Infant birth weight;   Infant initial glucose;   Infant complications
16 Unknown  Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide
Condition: Diabetes
Outcome Measure: HbA1c
17 Recruiting Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Condition: Diabetes
Interventions: Drug: metforminpioglitazoneexenatide;   Drug: metformin, glyburide and glargine
Outcome Measures: Difference in HbA1c level;   treatment failure;   hypoglycemic events
18 Recruiting Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
Interventions: Dietary Supplement: Vitamin C;   Drug: glyburide
Outcome Measures: improving the renal function;   Vitamin C can improve the visual fields
19 Recruiting Incretin and KATP Channels
Condition: Healthy Subjects
Intervention: Other: Intradermal injections of GLP-1 and its analogues
Outcome Measure: Change in skin blood flow to GLP-1 and its analogues
20 Unknown  Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Glibenclamide
Outcome Measures: Glucose threshold for development of symptoms and cognitive impairment due to hypoglycaemia;   Improvement in counter regulatory hormone response to hypoglycaemia

These studies may lead to new treatments and are adding insight into Daonil etiology and treatment.

A major focus of Daonil research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Daonil